161 related articles for article (PubMed ID: 3571436)
1. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC).
Sigal CE; Valone FH; Holtzman MJ; Goetzl EJ
J Clin Immunol; 1987 Mar; 7(2):179-84. PubMed ID: 3571436
[TBL] [Abstract][Full Text] [Related]
2. Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects.
Tamura N; Agrawal DK; Suliaman FA; Townley RG
Biochem Biophys Res Commun; 1987 Feb; 142(3):638-44. PubMed ID: 3030295
[TBL] [Abstract][Full Text] [Related]
3. New method for the measurement of eosinophil migration.
Håkansson L; Westerlund D; Venge P
J Leukoc Biol; 1987 Dec; 42(6):689-96. PubMed ID: 2445885
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro.
Alves AC; Pires AL; Cruz HN; Serra MF; Diaz BL; Cordeiro RS; Lagente V; Martins MA
Eur J Pharmacol; 1996 Sep; 312(1):89-96. PubMed ID: 8891583
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins.
Morita E; Schröder JM; Christophers E
Scand J Immunol; 1989 Jun; 29(6):709-16. PubMed ID: 2544988
[TBL] [Abstract][Full Text] [Related]
6. Chemotaxis of human neutrophils and eosinophils towards leukotriene B4 and its 20-w-oxidation products in vitro.
Czarnetzki BM; Rosenbach T
Prostaglandins; 1986 May; 31(5):851-8. PubMed ID: 3014612
[TBL] [Abstract][Full Text] [Related]
7. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
Wardlaw AJ; Moqbel R; Cromwell O; Kay AB
J Clin Invest; 1986 Dec; 78(6):1701-6. PubMed ID: 3023451
[TBL] [Abstract][Full Text] [Related]
8. Increased biosynthesis of platelet-activating factor in activated human eosinophils.
Lee T; Lenihan DJ; Malone B; Roddy LL; Wasserman SI
J Biol Chem; 1984 May; 259(9):5526-30. PubMed ID: 6425292
[TBL] [Abstract][Full Text] [Related]
9. Eosinophils isolated by magnetic cell sorting respond poorly to lipid chemoattractants.
Casale TB; Erger RA; Rozell MD
Ann Allergy Asthma Immunol; 1999 Aug; 83(2):127-31. PubMed ID: 10480585
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4.
Czarnetzki BM; Csatò M
Int Arch Allergy Appl Immunol; 1989; 88(1-2):191-3. PubMed ID: 2540094
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects.
Sehmi R; Wardlaw AJ; Cromwell O; Kurihara K; Waltmann P; Kay AB
Blood; 1992 Jun; 79(11):2952-9. PubMed ID: 1316789
[TBL] [Abstract][Full Text] [Related]
12. Effects of novel lipoxygenase products on migration of eosinophils and neutrophils in vitro.
Udén AM; Palmblad J; Lindgren JA; Malmsten C
Int Arch Allergy Appl Immunol; 1983; 72(1):91-3. PubMed ID: 6307891
[TBL] [Abstract][Full Text] [Related]
13. Triple role of platelet-activating factor in eosinophil migration across monolayers of lung epithelial cells: eosinophil chemoattractant and priming agent and epithelial cell activator.
Liu L; Zuurbier AE; Mul FP; Verhoeven AJ; Lutter R; Knol EF; Roos D
J Immunol; 1998 Sep; 161(6):3064-70. PubMed ID: 9743372
[TBL] [Abstract][Full Text] [Related]
14. Chemotactic responsiveness of eosinophils isolated from patients with inflammatory skin diseases.
Morita E; Schröder JM; Christophers E
J Dermatol; 1989 Oct; 16(5):348-51. PubMed ID: 2532224
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT; Kreukniet J
Br J Pharmacol; 1990 Apr; 99(4):798-802. PubMed ID: 2163279
[TBL] [Abstract][Full Text] [Related]
16. Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release.
Czarneztki BM
Chem Phys Lipids; 1982 Oct; 31(2):205-11. PubMed ID: 6814773
[TBL] [Abstract][Full Text] [Related]
17. In vivo activation of equine eosinophils and neutrophils by experimental Strongylus vulgaris infections.
Dennis VA; Klei TR; Chapman MR; Jeffers GW
Vet Immunol Immunopathol; 1988 Dec; 20(1):61-74. PubMed ID: 3238919
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies indicate that platelet-activating factor is a relatively weak eosinophilotactic mediator.
Erger RA; Casale TB
Am J Respir Cell Mol Biol; 1995 Jan; 12(1):65-70. PubMed ID: 7811471
[TBL] [Abstract][Full Text] [Related]
19. LTB4, a potent chemotactic factor for purified guinea-pig eosinophils: interference of PAF-acether antagonists.
Coëffier E; Joseph D; Vargaftig BB
Int J Immunopharmacol; 1991; 13(2-3):273-80. PubMed ID: 1649143
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene C4 production from human eosinophils in vitro. Role of eosinophil chemotactic factors on eosinophil activation.
Tamura N; Agrawal DK; Townley RG
J Immunol; 1988 Dec; 141(12):4291-7. PubMed ID: 2848892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
